Allergan, an AbbVie Company, and Von Miller Encourage People with Glaucoma to Design Their Disease Management Plan
|
NORTH CHICAGO, Ill., Oct. 8, 2020 /PRNewswire/ -- More than 4 million people in the United States are expected to have glaucoma by 2030. This serious disease is one of the leading causes of blindness, yet patients do not know that elevated eye pressure is the only treatable risk factor. Von Miller, Super Bowl MVP, Denver Broncos linebacker and advocate for healthy vision, knows first-hand how important it is to be proactive in taking control of vision-related issues. He is once again partnering with Allergan, an AbbVie Company, for My Glaucoma, My Design, which asks people living with glaucoma and their loved ones to share photos and stories on social media that show how they are managing their disease. This initiative ultimately encourages people with glaucoma and their caregivers to design an effective disease management plan with their doctors. Glaucoma is characterized by elevated intraocular pressure (IOP), the fluid pressure inside the eye. IOP is the only treatable risk factor for glaucoma. If left untreated, glaucoma patients continue to progress leading to vision loss and ultimately blindness. "Earlier this year, I partnered with Allergan to help bring awareness to the My Glaucoma campaign. I don't have glaucoma, but I struggled with vision-related issues when I was young and that is why I have a passion for encouraging people to be proactive in taking control of their eye health," said Von Miller. "I never realized how serious glaucoma can be and that uncontrolled eye pressure is the only treatable risk factor for glaucoma. I'm proud to be continuing my partnership with Allergan and taking the campaign to another level by educating people living with glaucoma so they can work with their doctors to design treatment plans that help lower eye pressure." People can share their My Glaucoma, My Design stories by going to the My Glaucoma Facebook page and submitting a photo along with a short description on how they are managing their glaucoma. Miller will select a few of his favorite stories to feature across Allergan and Miller's social channels. These individuals will also receive a personalized video message from Miller. This initiative aims at addressing the lack of awareness and education around the seriousness of glaucoma for people living with glaucoma and their caregivers. While current eye drop therapies can be effective to lower IOP, many patients struggle to administer their drops properly and consistently. In fact, based on a 71 patient study looking at eye drop instillation technique only 28% of people were able to instill eye drops correctly. Additionally, one small study showed people with glaucoma are at a 3 times greater risk of falls and 6 times greater risk for automobile accidents. "When we initially launched My Glaucoma, we wanted to reinforce that glaucoma is not just a part of aging and that it is a serious disease associated with elevated eye pressure that cannot be taken lightly," said Ramin Valian, Vice President, Interventional Glaucoma and Reimbursement, AbbVie. "With My Glaucoma, My Design, we are bringing to light patient stories and sharing resources that people living with glaucoma can use to ensure they are taking care of their disease and having informed treatment conversations with their eye doctor about lowering their eye pressure." My Glaucoma launched on World Sight Day 2019 with a survey designed to help people understand the burden of living with glaucoma and empower those with the disease and their caregivers to feel comfortable speaking with their doctor about a treatment plan that fits their lifestyle. During Glaucoma Awareness Month in 2020, Von Miller, partnered with Allergan to challenge people to learn more about the seriousness of glaucoma via an online quiz and shared his personal story about his vision-related issues. Please visit www.MyGlaucoma.com for more information. About Allergan Eye Care As a leader in eye care, Allergan has discovered, developed, and delivered some of the most innovative products in the industry for more than 70 years. Allergan has launched over 125 eye care products and invested billions of dollars in new treatments for the most prevalent eye conditions including glaucoma, ocular surface disease, and retinal diseases such as diabetic macular edema and retinal vein occlusion. Our eye care pipeline includes 13 additional agents for multiple ocular conditions. We remain steadfast in helping eye care providers deliver the best in patient care through innovative products and outreach programs. About AbbVie AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at http://www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, YouTube and LinkedIn. Forward-Looking Statements
SOURCE AbbVie |
View original content: